Second‐Line Antiretroviral Treatment Outcome in HIV‐Infected Patients Coinfected with Tuberculosis in Pakistan
BioMed Research International · 2023
DOI: 10.1155/2023/4187488 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2023. Verfasst von Muhammad Shafiq und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, COMSATS University Islamabad (CUI), Park Road, Chak Shahzad, Islamabad, Pakistan. Hauptthemen laut MEDLINE: HIV Infections, Coinfection, Tuberculosis, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tuberculosis (TB) coinfection in human immunodeficiency virus‐ (HIV‐) infected patients is considered a risk of antiretroviral therapy (ART) failure. Coadministration of antitubercular therapy (ATT) with ART is another challenge for TB management.
Objective
The study was aimed at investigating contributing factors affecting treatment outcomes in HIV‐/TB‐coinfected patients.
Design
Cross‐sectional.
Setting
Samples were collected from the Pakistan Institute of Medical Sciences Hospital Islamabad. Subject and Methods . Clinicodemographic and immunovirological factors between the two groups were compared. The Student t ‐test and chi‐square test were applied to compare outcome variables, and logistic regression was applied to determine the effect of TB on virological failure (VF). Main Outcome Measures . TB coinfection did not increase VF even in univariate ( p = 0.974) and multivariate analysis at 6 and 12 months of 2 nd ‐line ART start. ARV switching was significant ( p = 0.033) in TB‐coinfected patients. VF was significantly high in ATT‐coadministered patients along with a viral load of ≥1000 ( p = 0.000). Sample Size and Characteristics . We recruited seventy‐four HIV patients on 2 nd ‐line ART; 33 coinfected with TB were followed for at least 12 months.
Conclusion
In HIV‐/TB‐coinfected patients, CD4 count, CD4 gain, and VF remained comparable to HIV patients with no TB infection. ATT significantly affects the treatment outcome, suggesting drug‐to‐drug interactions. These factors are important to revisit the therapeutic guidelines to maximize the benefit of dual therapy in resource‐limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biosciences, COMSATS University Islamabad (CUI), Park Road, Chak Shahzad, Islamabad, Pakistan.
- Services Institute of Medical Sciences, Lahore, Punjab, Pakistan.
- Department of Microbiology, Kohsar University Murree, Punjab, Pakistan.
- Institute of Hydrobiology, Chinese Academy of Sciences, University of Chinese Academy of Sciences (UCAS), Wuhan, China.
- Dermatology Department, Combined Military Hospital (CMH) Kharian, Punjab, Pakistan.
- Pakistan Institute of Medical Science (PIMS), Islamabad, Pakistan.
ORCID-Profile: Abeer Kazmi, Saif Ur Rehman, Muhammad Adnan Shereen, Muhammad Zeeshan Hyder
Zitieren
APA
Shafiq, M., Zafar, S., Ahmad, A., Kazmi, A., Fatima, A., Mujahid, T. A., Qazi, R., Akhter, N., Shahzad, A., Rehman, S. U., Shereen, M. A., & Hyder, M. Z. (2023). Second‐Line Antiretroviral Treatment Outcome in HIV‐Infected Patients Coinfected with Tuberculosis in Pakistan. BioMed Research International. https://doi.org/10.1155/2023/4187488
Vancouver
Shafiq M, Zafar S, Ahmad A, Kazmi A, Fatima A, Mujahid TA, et al. Second‐Line Antiretroviral Treatment Outcome in HIV‐Infected Patients Coinfected with Tuberculosis in Pakistan. BioMed Research International. 2023. doi:10.1155/2023/4187488
BibTeX
@article{Shafiq2023,
author = {Shafiq, Muhammad and Zafar, Sana and Ahmad, Aftab and Kazmi, Abeer and Fatima, Alina and Mujahid, Tanvir Ahmed and Qazi, Rizwan and Akhter, Nasim and Shahzad, Amir and Rehman, Saif Ur and Shereen, Muhammad Adnan and Hyder, Muhammad Zeeshan},
title = {Second‐Line Antiretroviral Treatment Outcome in HIV‐Infected Patients Coinfected with Tuberculosis in Pakistan},
journal = {BioMed Research International},
year = {2023},
doi = {10.1155/2023/4187488}
}
EUVIMED